Eli Lilly stock was falling early Thursday even as the drugmaker posted first-quarter earnings that beat analysts’ ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Pfizer ( ($PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer (PFE) has been the focus of ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high ...

Goldman Sachs analyst Asad Haider maintained their bullish stance on the stock, giving it a Buy rating on April 8. The ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

With a market cap of $717 billion, Eli Lilly (LLY) is one of the world’s largest pharmaceutical companies. Lilly is ...

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

We recently published a list of 10 Dirt Cheap Stocks To Invest In Now. In this article, we are going to take a look at where ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.